Rationale: An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein enriched on malignant cells. Multiple ADCs are currently used clinically as anti-cancer agents significantly improving patient survival. Herein, we evaluated the rationale of targeting the cell surface oncoreceptor CUB domain-containing protein 1 (CDCP1) using ADCs and assessed the efficacy of CDCP1-directed ADCs against a range of malignant tumors. Methods: CDCP1 mRNA expression was evaluated using large transcriptomic datasets of normal/tumor samples for 23 types of cancer and 15 other normal organs, and CDCP1 protein expression was examined in 34 normal tissues, >300 samples from six ty...
CUB domain-containing protein 1 (CDCP1), also known as SIMA135, gp140, CD318, or Trask, is a transme...
Hematogenous metastases are rarely present at diagnosis of ovarian clear cell carcinoma (OCC). Inste...
The mechanisms by which prostate cancer shifts from an indolent castration-sensitive phenotype to le...
Background: CUB domain-containing protein 1 (CDCP1) is a cell surface receptor regulating key signal...
CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies p...
PURPOSE: Despite recent approvals for checkpoint inhibitors and antibody-drug conjugates targeting N...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
The function of CUB domain-containing protein 1 (CDCP1), a recently described transmembrane protein ...
In the last few years dysregulated expression of the cell surface glycoprotein CUB domain-containing...
Extracellular proteolysis is frequently dysregulated in disease and can generate proteoforms with un...
The transmembrane glycoprotein, CUB (complement C1r/C1s, Uegf, Bmp1) domain-containing protein 1 (CD...
CUB domain containing protein 1 (CDCPl) is an integral membrane glycoprotein that has been implicate...
We report the application of quantitative mass spectrometry to identify plasma membrane proteins dif...
Background: Deregulated expression of the transmembrane glycoprotein CDCP1 (CUB domain-containing pr...
Summary In the last few years dysregulated expression of the cell surface glycoprotein CUB domain-co...
CUB domain-containing protein 1 (CDCP1), also known as SIMA135, gp140, CD318, or Trask, is a transme...
Hematogenous metastases are rarely present at diagnosis of ovarian clear cell carcinoma (OCC). Inste...
The mechanisms by which prostate cancer shifts from an indolent castration-sensitive phenotype to le...
Background: CUB domain-containing protein 1 (CDCP1) is a cell surface receptor regulating key signal...
CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies p...
PURPOSE: Despite recent approvals for checkpoint inhibitors and antibody-drug conjugates targeting N...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
The function of CUB domain-containing protein 1 (CDCP1), a recently described transmembrane protein ...
In the last few years dysregulated expression of the cell surface glycoprotein CUB domain-containing...
Extracellular proteolysis is frequently dysregulated in disease and can generate proteoforms with un...
The transmembrane glycoprotein, CUB (complement C1r/C1s, Uegf, Bmp1) domain-containing protein 1 (CD...
CUB domain containing protein 1 (CDCPl) is an integral membrane glycoprotein that has been implicate...
We report the application of quantitative mass spectrometry to identify plasma membrane proteins dif...
Background: Deregulated expression of the transmembrane glycoprotein CDCP1 (CUB domain-containing pr...
Summary In the last few years dysregulated expression of the cell surface glycoprotein CUB domain-co...
CUB domain-containing protein 1 (CDCP1), also known as SIMA135, gp140, CD318, or Trask, is a transme...
Hematogenous metastases are rarely present at diagnosis of ovarian clear cell carcinoma (OCC). Inste...
The mechanisms by which prostate cancer shifts from an indolent castration-sensitive phenotype to le...